更正：达贝泊肽α注射液替代环氧乙烷α注射液治疗中国血液透析患者肾性贫血的有效性和安全性：随机、开放标签、平行分组、非劣效性III期试验

Q1 Medicine

Chronic Diseases and Translational Medicine Pub Date : 2023-09-19 DOI:10.1002/cdt3.94

{"title":"更正：达贝泊肽α注射液替代环氧乙烷α注射液治疗中国血液透析患者肾性贫血的有效性和安全性：随机、开放标签、平行分组、非劣效性III期试验","authors":"","doi":"10.1002/cdt3.94","DOIUrl":null,"url":null,"abstract":"In the article titled, “Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial” published in pages 134-144, issue 2, vol. 8 of Chronic Diseases and Translational Medicine,1 the information of trial registration at the end of Abstract is missing. The registration information should be: This study has been registered on www.chinadrugtrials.org.cn, registered number CTR20130079.","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.94","citationCount":"0","resultStr":"{\"title\":\"Corrigendum: Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial\",\"authors\":\"\",\"doi\":\"10.1002/cdt3.94\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the article titled, “Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial” published in pages 134-144, issue 2, vol. 8 of Chronic Diseases and Translational Medicine,1 the information of trial registration at the end of Abstract is missing. The registration information should be: This study has been registered on www.chinadrugtrials.org.cn, registered number CTR20130079.\",\"PeriodicalId\":32096,\"journal\":{\"name\":\"Chronic Diseases and Translational Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.94\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Chronic Diseases and Translational Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cdt3.94\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic Diseases and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cdt3.94","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

慢性病转化医学》第 8 卷第 2 期第 134-144 页刊登了题为 "达贝泊汀α注射液替代环氧乙烷α注射液治疗中国血液透析患者肾性贫血的有效性和安全性：慢性病与转化医学》1 第 8 卷第 2 期第 134-144 页发表的文章 "A randomized, open-label, parallel-group, noninferiority phase III trial: A randomized, open-label, parallel-group, noninferiority trial"（一项随机、开放标签、平行组、非劣效性 III 期试验），摘要末尾缺少试验注册信息。注册信息应为本研究已在 www.chinadrugtrials.org.cn 上注册，注册号为 CTR20130079。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Corrigendum: Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial

In the article titled, “Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open-label, parallel-group, noninferiority phase III trial” published in pages 134-144, issue 2, vol. 8 of Chronic Diseases and Translational Medicine,¹ the information of trial registration at the end of Abstract is missing. The registration information should be: This study has been registered on www.chinadrugtrials.org.cn, registered number CTR20130079.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Chronic Diseases and Translational Medicine Medicine-General Medicine

CiteScore

6.70

自引率

0.00%

发文量

195

审稿时长

35 weeks

期刊介绍： This journal aims to promote progress from basic research to clinical practice and to provide a forum for communication among basic, translational, and clinical research practitioners and physicians from all relevant disciplines. Chronic diseases such as cardiovascular diseases, cancer, diabetes, stroke, chronic respiratory diseases (such as asthma and COPD), chronic kidney diseases, and related translational research. Topics of interest for Chronic Diseases and Translational Medicine include Research and commentary on models of chronic diseases with significant implications for disease diagnosis and treatment Investigative studies of human biology with an emphasis on disease Perspectives and reviews on research topics that discuss the implications of findings from the viewpoints of basic science and clinical practic.